News Sentiment

XENE sentiment intelligence

Xenon Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 58 Balanced news tone 55 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 68.92 Week of 10 Jul 2026
Weighted tone 58/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

80/100 classification confidence.

Company focus 47

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend active

+13.1% over one week, +32.3% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

Xenon Pharmaceuticals (XENE) Could Be 14% Undervalued If Its Epilepsy Narrative Holds

Market Reaction

Price moving ahead of tone

68/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 80/100 classification
One-week reaction 13.1% Price confirming higher
Trend fit Trend active 32.3% over four weeks
Fair value 67.8% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 20
Neutral 34
Negative 1

Relevance

Why the article matched

Direct first
Direct company coverage 47
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 12
Stock Titan 7
TradingView 6
simplywall.st 5
TradingKey 4
Stock Traders Daily 2
Investing.com 2
Finviz 2

Event Lens

What the news is about

Classified themes
Market update 30
Earnings 19
Balance sheet 3
Analyst action 3

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 55
Sahm Direct company coverage

Xenon Pharmaceuticals (XENE) Could Be 14% Undervalued If Its Epilepsy Narrative Holds

Xenon Pharmaceuticals (XENE) is attracting investor attention due to its recent stock performance and late-stage epilepsy program. While a common valuation narrative suggests the company is 14.4% undervalued based on aggressive growth projections and future earnings, this hinges

Tone
Positive 63/100
Event
Earnings
Published
14 Jul 2026 13:45
Source
Sahm
TradingView Direct company coverage

Price to sales forward of Xenon Pharmaceuticals Inc. – BIVA:XENE/N

This article provides the "Price to sales forward" for Xenon Pharmaceuticals Inc. (BIVA:XENE/N) as listed on TradingView. It appears to be a financial data snippet rather than a news article, focusing specifically on this one metric for the company. The page indicates no trades w

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 06:12
Source
TradingView
Stock Traders Daily Direct company coverage

Understanding the Setup: (XENE) and Scalable Risk

Xenon Pharmaceuticals Inc. (XENE) shows strong sentiment across all horizons, supporting an overweight bias with compelling upside potential due to no resistance levels remaining above the current price. AI models have generated three distinct trading strategies—Position Trading,

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 22:46
Source
Stock Traders Daily
Investing.com Direct company coverage

Xenon Pharmaceuticals stock hits all-time high at 63.96 USD

Xenon Pharmaceuticals Inc. (XENE) recently saw its stock price reach an all-time high of $63.96, surpassing its 52-week high and reflecting a 1-year gain of over 102%. This strong performance comes despite reporting zero revenue in Q1 2026, though EPS exceeded forecasts. Analysts

Tone
Positive 75/100
Event
Earnings
Published
07 Jul 2026 17:41
Source
Investing.com
TradingView Direct company coverage

Enterprise value to revenue forward of Xenon Pharmaceuticals Inc. – NASDAQ:XENE

This article focuses on the "Enterprise value to revenue forward" metric for Xenon Pharmaceuticals Inc. (NASDAQ: XENE). Although the provided content is largely navigational and informational about the TradingView platform, it specifically highlights this financial ratio within t

Tone
Neutral 50/100
Event
Earnings
Published
05 Jul 2026 00:42
Source
TradingView
TradingView Direct company coverage

Price to book forward of Xenon Pharmaceuticals Inc. – NASDAQ:XENE

This article displays the "Price to book forward" for Xenon Pharmaceuticals Inc. (NASDAQ: XENE). The content is primarily a data point with no further analysis or discussion. It indicates the latest value for this financial metric for the specified company.

Tone
Neutral 50/100
Event
Market update
Published
05 Jul 2026 00:40
Source
TradingView
Moomoo Direct company coverage

We're Not Very Worried About Xenon Pharmaceuticals' (NASDAQ:XENE) Cash Burn Rate

Xenon Pharmaceuticals (NASDAQ:XENE) has a cash runway of 3.6 years based on its US$1.1 billion cash reserves in March 2026 and a US$307 million cash burn rate. While its cash burn increased by 54% last year, analysts project the company will break even within approximately four y

Tone
Positive 64/100
Event
Balance sheet
Published
04 Jul 2026 09:40
Source
Moomoo
Finviz Direct company coverage

XENE - Xenon Pharmaceuticals Inc Volatility & Greeks

This article provides a detailed financial overview of Xenon Pharmaceuticals Inc. (XENE), including its latest stock performance, key financial metrics, volatility indicators, and analyst recommendations. It highlights the company's market capitalization, income, sales, and vario

Tone
Neutral 50/100
Event
Analyst action
Published
04 Jul 2026 01:11
Source
Finviz
GlobeNewswire Direct company coverage

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Xenon Pharmaceuticals Inc. announced equity inducement grants to four new non-officer employees, consisting of 20,200 share options and 11,850 restricted share units (RSUs). These grants were approved by the Compensation Committee and are material inducements for employment, in c

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 09:40
Source
GlobeNewswire
TradingView Direct company coverage

Price to earnings forward of Xenon Pharmaceuticals Inc. – NASDAQ:XENE

The article focuses on the "Price to earnings forward" financial metric for Xenon Pharmaceuticals Inc. (NASDAQ: XENE) as presented on the TradingView platform. It provides the company's stock symbol and market information, indicating that the market was closed at the time the dat

Tone
Neutral 50/100
Event
Earnings
Published
03 Jul 2026 01:41
Source
TradingView
Stock Titan Direct company coverage

Xenon awards new hires 20,200 options and 11,850 RSUs

Xenon Pharmaceuticals Inc. (Nasdaq: XENE) has granted equity inducement awards to four new non-officer employees, consisting of 20,200 share options and 11,850 restricted share units (RSUs). These grants, approved by the Compensation Committee, have an exercise price of $60.30 an

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 20:04
Source
Stock Titan
Finviz Direct company coverage

XENE - Xenon Pharmaceuticals Inc Latest SEC Filings

This article provides the latest SEC filings and comprehensive financial data for Xenon Pharmaceuticals Inc. (XENE). It includes key financial metrics, performance indicators, insider/institutional ownership details, and analyst recommendations, offering a detailed snapshot of th

Tone
Neutral 50/100
Event
Analyst action
Published
02 Jul 2026 05:41
Source
Finviz
TradingView Direct company coverage

Enterprise value to EBIT forward of Xenon Pharmaceuticals Inc. – NASDAQ:XENE

This article focuses on the enterprise value to EBIT forward for Xenon Pharmaceuticals Inc. (NASDAQ: XENE). It appears to be a financial data point or a report generated by TradingView, a financial platform. The content primarily lists navigation and footer information related to

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 12:10
Source
TradingView
Stock Traders Daily Direct company coverage

The Technical Signals Behind (XENE) That Institutions Follow

This article analyzes Xenon Pharmaceuticals Inc. (NASDAQ: XENE) using AI models to identify institutional trading signals. It highlights strong sentiment across all horizons, an exceptional risk-reward setup, and provides three distinct trading strategies: a Position Trading Stra

Tone
Positive 73/100
Event
Market update
Published
29 Jun 2026 21:38
Source
Stock Traders Daily
Simply Wall Street Direct company coverage

Is Positive X-TOLE2 Epilepsy Data And 2026 FDA Filing Plan Altering The Investment Case For Xenon Pharmaceuticals (XENE)?

Xenon Pharmaceuticals recently announced positive Phase III X-TOLE2 results for azetukalner in focal onset seizures and plans to submit a new drug application to the FDA for this indication in Q3 2026. This progress advances azetukalner within the company's neuroscience pipeline

Tone
Positive 71/100
Event
Earnings
Published
24 Jun 2026 13:41
Source
Simply Wall Street
Market source Direct company coverage

Xenon Pharmaceuticals Stock Gains 22% in Six Months: Here's Why

Xenon Pharmaceuticals (XENE) stock has surged 22% over the past six months, outperforming the industry's decline, driven by strong investor confidence in its neuroscience pipeline. Key to this growth is azetukalner, the company's lead asset, which showed positive phase III result

Tone
Positive 74/100
Event
Market update
Published
23 Jun 2026 17:11
Source
Market source
Quartr Direct company coverage

Xenon Pharmaceuticals (XENE) Q4 2025 earnings summary

Xenon Pharmaceuticals released its Q4 2025 earnings, highlighting significant progress in Phase 3 clinical trials for azetukalner in epilepsy and neuropsychiatry, with NDA submission expected in 2026. The company expanded its early-stage pipeline and raised $242.2 million through

Tone
Positive 62/100
Event
Earnings
Published
23 Jun 2026 04:40
Source
Quartr
TradingKey Direct company coverage

Xenon Pharmaceuticals Inc (XENE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

The article provides a revenue breakdown for Xenon Pharmaceuticals Inc (XENE), including its stock performance, market capitalization, and financial overview. It notes that relevant data regarding business segments, regional revenue, and profit contribution for recent fiscal year

Tone
Neutral 50/100
Event
Earnings
Published
18 Jun 2026 06:10
Source
TradingKey
TradingKey Direct company coverage

Xenon Pharmaceuticals Inc (XENE) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Xenon Pharmaceuticals Inc (XENE), including its major shareholders and institutional holdings. It lists the top individual shareholders like Fidelity Management & Research Company LLC and Avoro Capital Advisors LLC, as well as cat

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 01:10
Source
TradingKey
TradingKey Direct company coverage

Xenon Pharmaceuticals Inc (XENE) Institutional Confidence

Xenon Pharmaceuticals Inc (XENE) has an institutional confidence score of 10.00, ranking 1st in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 116.66%, a 21.96% increase quarter-over-quarter. Paul Tudor Jones is the largest institution

Tone
Positive 70/100
Event
Market update
Published
17 Jun 2026 08:41
Source
TradingKey
TradingKey Direct company coverage

Xenon Pharmaceuticals Inc (XENE) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Xenon Pharmaceuticals Inc (XENE), highlighting its current earnings forecast score, analyst ratings, and price targets. It includes a peer comparison and addresses frequently asked questions regarding expected revenue, price targets,

Tone
Positive 74/100
Event
Earnings
Published
17 Jun 2026 08:41
Source
TradingKey
Market source Direct company coverage

Assessing Xenon Pharmaceuticals (XENE) Valuation After Recent Share Price Pullback And Modest Undervaluation Estimate

Xenon Pharmaceuticals (XENE) recently experienced a share price pullback, with the stock down around 3% in the past day and 4% in the last week, yet it has shown strong performance over the past year. Despite the recent dip, Simply Wall St assesses XENE as modestly undervalued at

Tone
Positive 63/100
Event
Market update
Published
11 Jun 2026 17:39
Source
Market source
MarketBeat Direct company coverage

Fiera Capital Corp Boosts Stock Position in Xenon Pharmaceuticals Inc. $XENE

Fiera Capital Corp increased its stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 31.9% in the fourth quarter, bringing its total holdings to 686,056 shares valued at $30.7 million. Several other institutional investors also increased their positions, indicating significant i

Tone
Positive 76/100
Event
Earnings
Published
09 Jun 2026 23:39
Source
MarketBeat
Stock Titan Direct company coverage

Xenon (XENE) director Patou sells 1,322 shares in tax-related 10b5-1 trade

Xenon Pharmaceuticals director Gary Patou sold 1,322 shares of XENE stock at $53.14 per share on June 5, 2026. This transaction was conducted under a pre-planned Rule 10b5-1 trading plan adopted in August 2025, specifically to cover income tax obligations from the vesting of rest

Tone
Neutral 50/100
Event
Market update
Published
09 Jun 2026 01:39
Source
Stock Titan
Stock Titan Direct company coverage

Xenon Pharmaceuticals (XENE) director Cannon sells 1,190 shares under 10b5-1 tax plan

Xenon Pharmaceuticals Inc. director Gillian Cannon sold 1,190 common shares at an average price of $53.14 per share on June 5, 2026. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted in August 2025, primarily to cover income tax obligations from

Tone
Neutral 50/100
Event
Market update
Published
09 Jun 2026 01:39
Source
Stock Titan
Stock Titan Direct company coverage

[144] Xenon Pharmaceuticals Inc. SEC Filing

This article reports on a Form 144 SEC filing by Xenon Pharmaceuticals Inc. (XENE), detailing a proposed sale of 1,322 common shares by an insider. The filing indicates the securities were acquired on May 31, 2026, as Restricted Stock Units from the issuer. The aggregated market

Tone
Neutral 50/100
Event
Market update
Published
07 Jun 2026 12:39
Source
Stock Titan